We are live on ! Find out more
ISPC icon

iSpecimen

13 hedge funds and large institutions have $665K invested in iSpecimen in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more funds holding

Funds holding: 1113 (+2)

2% more capital invested

Capital invested by funds: $653K → $665K (+$12.4K)

0% more ownership

Funds ownership: 0.01%0.01% (+0%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
13
Holders Change
+2
Holders Change %
+18.18%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
4
Closed
Calls
Puts
Net Calls
Net Calls Change

ISPC Hedge Fund Activity: Q1 2023 in Review

13 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in iSpecimen (ISPC) for Q1 2023, worth a combined $665K — up 1.9% from $653K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new ISPC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Northern Trust, opening a new position worth an estimated $20.6K. The largest seller was Tower Research Capital (TRC), cutting an estimated $3.64K.

  • 13 institutional investors held iSpecimen (ISPC) as of Q1 2023, up from 11 in Q4 2022.
  • Funds reported $665K of iSpecimen stock for Q1 2023, up 1.9% quarter-over-quarter.
  • 2 funds opened new iSpecimen positions in Q1 2023 and 0 closed out, a net change of +2 holders.
  • The largest iSpecimen buyer in Q1 2023 was Northern Trust, an estimated $20.6K added.
  • The largest iSpecimen seller in Q1 2023 was Tower Research Capital (TRC), an estimated $3.64K sold.

Based on aggregated 13F filings for Q1 2023.